Psoas Abscess as a Differential Diagnosis of Neuroleptic Malignant Syndrome in a Schizoaffective Disorder Patient With Catatonic Symptoms

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

To the Editor: The prevalence of neuroleptic malignant syndrome (NMS) is estimated to be 0.9/1,000 people. The clinical presentation is heterogeneous, especially in the early phase. Although it is historically associated with the typical antipsychotics, it is also a potential adverse effect of atypical antipsychotics.